Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Ladd, B., Mazzola, A.M., Bihani, T. et al. (17 more authors) (2016) Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget.

Abstract

Metadata

Authors/Creators:
  • Ladd, B.
  • Mazzola, A.M.
  • Bihani, T.
  • Lai, Z.
  • Bradford, J. ORCID logo https://orcid.org/0000-0002-7771-914X
  • Collins, M.
  • Barry, E.
  • Goeppert, A.U.
  • Weir, H.M.
  • Hearne, K.
  • Renshaw, J.G.
  • Mohseni, M.
  • Hurt, E.
  • Jalla, S.
  • Bao, H.
  • Hollingsworth, R.
  • Reimer, C.
  • Zinda, M.
  • Fawell, S.
  • D'Cruz, C.M.
Copyright, Publisher and Additional Information: © 2016 Author(s). Oncotarget applies the Creative Commons Attribution License (CCAL) to all works we publish (https://creativecommons.org/licenses/by/3.0/). Under the CCAL, authors retain ownership of the copyright for their article, but authors allow anyone to download, reuse, reprint, modify, distribute, and/or copy articles in Oncotarget journal, so long as the original authors and source are cited. For queries about the license, please contact us at publisher@oncotarget.com
Keywords: ER mutations; advanced metastatic breast cancer; combination therapy; endocrine resistance
Dates:
  • Accepted: 6 July 2016
  • Published (online): 26 July 2016
  • Published: 26 July 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 16 Aug 2016 09:21
Last Modified: 16 Aug 2016 09:21
Published Version: http://dx.doi.org/10.18632/oncotarget.10852
Status: Published
Publisher: Impact Journals
Refereed: Yes
Identification Number: https://doi.org/10.18632/oncotarget.10852
Related URLs:

Export

Statistics